Navigation Links
Poniard Announces Positive First-Line Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in Patients with Metastatic Hormone Refractory Prostate Cancer
Date:5/31/2008

- Poster Presented at ASCO Annual Meeting -

SOUTH SAN FRANCISCO, Calif. and CHICAGO, May 31 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today presented preliminary safety and efficacy data from its ongoing Phase 2 clinical trial of picoplatin in combination with docetaxel and prednisone, the standard of care for the first-line treatment of metastatic hormone-refractory prostate cancer (HRPC). Results demonstrated that picoplatin can be safely administered with full doses of docetaxel. In addition, the prostate specific antigen (PSA) response rate was 69 percent in 26 patients evaluable for PSA.

The Company presented the Phase 2 data (abstract #5153) in the General Poster Session during the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) at McCormick Place in Chicago. Picoplatin, the Company's lead product candidate, is a new generation platinum chemotherapy agent with the potential to become a platform product addressing multiple indications, combinations and formulations.

"The promising results of this Phase 2 trial in HRPC support further development of picoplatin in the treatment of prostate cancer," said Robert De Jager, M.D., chief medical officer of Poniard. "A prospective randomized trial is under consideration. The combination of picoplatin with a taxane could be further evaluated in other tumor types, such as ovarian cancer and non-small cell lung cancer."

Phase 2 HRPC Study Preliminary Results

In the ongoing Phase 2 trial, the efficacy and safety of intravenous picoplatin (120 mg/m squared) administered every 21 days in combination with full-dose docetaxel (75 mg/m squared) with dail
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting
2. Poniard Pharmaceuticals Licenses Kinase Inhibitors From The Scripps Research Institute
3. Poniard Pharmaceuticals Completes Enrollment of Phase 2 Picoplatin Trial in Colorectal Cancer
4. Poniard Pharmaceuticals Announces Final Picoplatin Data from Phase 2 Small Cell Lung Cancer Trial Demonstrating Survival Benefit
5. Poniard Pharmaceuticals Oral Picoplatin Demonstrates Positive Bioavailability in Ongoing Phase 1 Trial
6. Poniard Pharmaceuticals Announces Presentation of Clinical Data From Picoplatin Phase 2 Small Cell Lung Cancer Trial to be Presented at 1st IASLC-ESMO European Lung Cancer Conference
7. Poniard Pharmaceuticals Announces Commercial Manufacturing Agreement With W. C. Heraeus GmbH for Picoplatin
8. Poniard Pharmaceuticals Announces Clinical Data From Picoplatin Oral Phase 1 to Be Presented at the American Association of Cancer Research Annual Meeting
9. Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients
10. Poniard Pharmaceuticals Announces Picoplatin Safety Data in Colorectal Cancer
11. Poniard Pharmaceuticals Provides Year-End Clinical Update at 2007 Lazard Capital Markets Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... , Sept. 2, 2014  Hologic, Inc. (NASDAQ: ... and Chief Executive Officer, will present at the Morgan Stanley ... , New York on Tuesday, September ... parties are invited to listen to the live audio webcast ... at www.hologic.com/investors-overview . An archive of the presentation will ...
(Date:9/2/2014)... SEATTLE , Sept. 2, 2014 /PRNewswire/ ... company committed to the development and commercialization ... today announced an update on corporate and ... structure, commitment for future funding, ongoing clinical ... In corporate news, Chief Executive Officer ...
(Date:9/2/2014)...  BioSpecifics Technologies Corp. (NASDAQ: BSTC ), a ... XIAFLEX ® in the U.S. and XIAPEX ® ... Wegman , will present at the following upcoming investor conferences. ... & Renshaw 16 th Annual Global Investment Conference ... 9, 2014 at 9:10 a.m. EDT , Aegis ...
Breaking Medicine Technology:VentiRx Pharmaceuticals Provides Corporate and Clinical Update 2VentiRx Pharmaceuticals Provides Corporate and Clinical Update 3BioSpecifics Technologies Corp. Announces Presentations at Upcoming Investor Conferences 2
... (NASDAQ: AMRI ), a global contract services organization ... as part of its ongoing global operations review to improve ... its European operations focused on a reduction of the workforce ... at its Budapest, Hungary operation. As a ...
... Jan. 9, 2012  Xenon today announced a strategic alliance ... RO, ROG; OTCQX: RHHBY), to discover and develop compounds ... "We are delighted to be collaborating with ... "Genentech is among the world,s leading biotech companies and ...
Cached Medicine Technology:AMRI Announces Review of Its Hungary Operation 2AMRI Announces Review of Its Hungary Operation 3Xenon to Collaborate with Genentech on Discovery of Novel Targeted Pain Therapeutics 2
(Date:9/2/2014)... 02, 2014 Welcome to Arthritis ... 4.6 million Canadians living with the disease, The Arthritis ... Arthritis” video series featuring well-known Canadians from different walks ... ,      Lloyd Robertson , veteran news anchor ... skier ,      Amy Cotton , two-time ...
(Date:9/2/2014)... prevalence of opioid-involved overdoses has become an increasing concern ... to the New York City Department of Health and ... in 2011 was nearly triple the number of such ... attributed to a dramatic rise in nonmedical prescription opioid ... recently, in heroin use among youth who transitioned from ...
(Date:9/2/2014)... research studies have made it clear that a mother,s ... lactation have a profound impact on her offspring and ... However, until now, the mechanisms behind this phenomenon were ... 2014 issue of The FASEB Journal F ... link between a mother,s diet and an offspring,s risk ...
(Date:9/2/2014)... PA (PRWEB) September 02, 2014 ... communications and education, is proud to announce the acquisition ... clinical resource center designed for healthcare professionals who integrate ... offers practitioners comprehensive access to:, , ... Dedicated topic centers for diabetes, oncology, renal ...
(Date:9/2/2014)... ROCHESTER, Minn. How well patients recover from ... their medical conditions and the operations themselves. Family ... risk of surgical complications, a Mayo Clinic study ... operation may reduce patients, stress, speed their recoveries ... The study specifically looked at colon cancer patients, ...
Breaking Medicine News(10 mins):Health News:‘Voices of Arthritis’ Launches Awareness Month 2Health News:‘Voices of Arthritis’ Launches Awareness Month 3Health News:NYC teens and young adults who abuse prescription at high risk for overdose 2Health News:NYC teens and young adults who abuse prescription at high risk for overdose 3Health News:How genes link a mother's diet to the risk of obesity in her offspring 2Health News:HMP Communications Holdings, LLC, Acquires Nutrition411.com 2Health News:Family conflicts, other non-physical worries before cancer surgery raise patients' complication risk 2
... time you load on the sauce, onto your pizza or spaghetti, ... ones//. , Scientists from Ohio State University have ... tomatoes, is absorbed better by the body, when it comes from ... study is published in the Journal of Agricultural and Food Chemistry. ...
... Defense Services will be bound by a Supreme Court order ... fired due to their health condition. , ,Last week ... soldiers and naval officers with HIV or AIDS. They could ... unsuitable for work. ,Senior officials in the army ...
... that the hormone glucocorticoids may not be as beneficial ... prescribed by many specialists as a thrust to infertility ... glucocorticoids are employed by many specialists to treat infertility, ... responses in a good manner. They are used to ...
... Remanence of anthrax spores in Smailholm and the border ... a decontamination operation// at a village hall where drumming ... deputed the New York-based specialists Sabre, to look into ... of anthrax evident in certain areas in Northumberland and ...
... accident that left a father and young daughter dead in ... ,Two people were killed Monday after the single-engine ... a small local airport in Bedford - into the home ... of the former mother-in-law of the divorced 47-year-old pilot, The ...
... who was seen visibly limping at a film awards function ... film 'Drona' in Bikaner last month. ,'She ... ignored it and kept shooting right through the injury. Because ... Filmfare awards show and even in parliament,' Amitabh Bachchan, Jaya's ...
Cached Medicine News:Health News:Pass the Orange Tomato Sauce Please 2
The True Non-Compliant Balloon....
... Jude Medical® Pacing System Analyzer (PSA Wand), ... implantation testing, programming and interrogation of bradycardia ... easy-to-use accessory to the St. Jude Medical ... obtaining measurements of intrinsic P- and R-wave ...
... The Finnpipette BioControl multichannel ... features as the single ... handle fits all seven ... channel tip cone modules. ...
... Long series in colonies, rows, and microplatesthat ... the multichannel pipette is becoming an ever-increasing ... use) was the main reason that the ... 8- or 12-channel pipette provides effective, precise, ...
Medicine Products: